Across TCGA pan-cancer cohorts, KRTAP4-12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP4-12 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher KRTAP4-12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP4-12 expression acts as an unfavorable survival marker.

BRCA, LUAD, and CESC are the cancer types where KRTAP4-12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.313	0.924	<.001	36	view →
LUAD	OS	Median	All	0.256	0.837	<.001	34	view →
CESC	OS	Median	All	0.132	0.875	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP4-12 tumor-vs-normal RNA expression · all KRTAP4-12 data types